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Background: We reported the first case of successful transapical transcatheter aortic valve implantation in a
human subject in 2005 and have now completed a 12-month follow-up on our first 26 patients. This is, to
date, the longest follow-up of patients undergoing transapical aortic valve implantation.
Methods: Between October 2005 and January 2007, 26 patients (13 female) underwent transcatheter transapical
aortic valve implantation with either 23- or 26-mmEdwards Lifesciences transcatheter bioprostheses. All patients
with symptomatic aortic stenosis were declined for conventional aortic valve replacement because of unaccept-
able operative risks and were not candidates for transfemoral aortic valve implantation because of poor arterial
access. Clinical and echocardiographic follow-up was performed before discharge and at 1, 6, and 12 months.
Data from the 17 patients who survived over 12 months were used for comparisons of the baseline and
follow-up results.
Results: The mean age was 80  9 years, and the predicted operative mortality was 37%  20% by using
logistic EuroSCORE and 11%  6% by using the Society of Thoracic Surgeons Risk Calculator. Valves
were successfully implanted in all patients. Six patients died within 30 days (30-day mortality, 23%), and 3
patients died from noncardiovascular causes after 30 days (late mortality, 12%). Among patients who survived
at least 30 days, 12-month survival was 85%. There were no late valve-related complications. New York Heart
Association functional class improved significantly. The aortic valve area and mean gradient remained stable at
12 months (1.6  0.3 cm2 and 9.6  4.8 mm Hg, respectively).
Conclusion: Our 1-year clinical and echocardiographic outcomes suggest that transapical transcatheter aortic
valve implantation is a viable alternative to conventional aortic valve replacement in selected high-risk patients.E
TAortic valve replacement (AVR) with cardiopulmonary
bypass (CPB) has been the only treatment that offers both
symptomatic relief and the potential for improved long-
term survival and hence is the treatment of choice for
patients with symptomatic severe degenerative aortic steno-
sis.1 However, because a considerable number of elderly
patients with symptomatic severe aortic stenosis have signif-
icant comorbidities, open-heart AVR with CPB can be asso-
ciated with an unacceptable perioperative mortality and
morbidity. Therapeutic options for these patients are limited,
and neither medical therapy nor balloon valvuloplasty offers
survival benefit. Over the past several years, the develop-
ment of minimally invasive transcatheter valve implantation
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doi:10.1016/j.jtcvs.2008.08.028The Journal of Thoracic andhas been explored.2-13 A percutaneous alternative was first
developed in an animal model by Andersen and col-
leagues.2,14 Subsequently, a number of groups pursued var-
ious approaches to transcatheter aortic valve implantation
(AVI).2-5,14-18 It was not until a decade after it was initially
proposed that the feasibility of percutaneous AVI was dem-
onstrated in human subjects by Cribier and associates7,8 us-
ing a transvenous transseptal approach. Subsequently, we
described a retrograde procedure using percutaneous femo-
ral artery access.10We reported the first successful transcath-
eter transapical AVI through a left minithoracotomy and the
apex of the left ventricle without CPB in human subjects in
200611,12 and then our initial experience of transapical trans-
catheter AVI without CPB in our first 10 patients.19,20 We
have now completed a 12-month clinical and echocardio-
graphic follow-up in our first 26 patients who underwent
transapical transcatheter AVI without CPB.
MATERIALS AND METHODS
The transapical procedure was approved by the Therapeutic Products
Directorate, Department of Health and Welfare, Ottawa, Canada, for com-
passionate clinical use in patients with symptomatic severe aortic stenosis
deemed not to be candidates for routine open-heart AVR and unsuitable
for percutaneous transfemoral AVI. All patients were assessed indepen-
dently by at least 2 cardiologists and 2 cardiac surgeons and accepted for
the procedure based on the consensus that conventional surgical interven-
tion was excessively high risk in terms of anticipated mortality andCardiovascular Surgery c Volume 137, Number 1 167
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TAbbreviations and Acronyms
AVI ¼ aortic valve implantation
AVR ¼ aortic valve replacement
CPB ¼ cardiopulmonary bypass
NYHA ¼ New York Heart Association
STS ¼ Society of Thoracic Surgeons
TEE ¼ transesophageal echocardiography
morbidity. Patient or physician preference alone was not considered ade-
quate. Written informed consent was obtained.
Patients
Patients who were accepted for transcatheter AVI were initially assessed
for suitability for percutaneous transfemoral AVI. Patients underwent
preoperative work-up, including coronary and aortofemoral angiography
and transthoracic echocardiography (TTE). Transesophageal echocardiog-
raphy (TEE) was performed when the diameter of the aortic annulus could
not be easily measured from the TTE images or a more accurate measure-
ment was required. Transapical AVI was recommended if aortofemoral an-
giographic analysis revealed unfavorable anatomy of the aorta, iliofemoral
arteries, or both for the transfemoral approach.
Prosthetic Valve Implantation
The procedure of transapical transcatheter AVI was described in detail in
our previous publications.11,19,20 Briefly, the procedure was performed after
achievement of general anesthesia in an operating room. The apex of the left
ventricle was identified by using a portable C-arm fluoroscopy and exposed
through an approximately 5-cm anterolateral minithoracotomy and a small
pericardial incision. Two paired orthogonal U-shaped sutures with pledgets
were placed into the myocardium and passed through tensioning tourni-
quets. Epicardial pacing wires were used for rapid ventricular pacing during
aortic valvuloplasty and deployment of the prosthesis.
Heparin was administered to achieve an activated clotting time of greater
than 250 seconds. Using fluoroscopic, aortographic, and TEE imaging, bal-
loon valvuloplasty and then deployment of the bioprosthesis were per-
formed during rapid ventricular pacing to minimize ventricular ejection
without CPB (Figure 1).We used balloon-expandable transcatheter biopros-
theses (SAPIENTM THV; Edwards Lifesciences, Inc, Irvine, Calif).
Twenty-three–millimeter bioprostheses were used in 6 patients, and 26-
mm bioprostheses were used in 20 patients. CPB was not used in any pa-
tient. Patients were maintained on aspirin indefinitely and clopidogrel for
at least 1 month. Warfarin was initially used in some patients who under-
went transapical AVI, but this was abandoned because of the frequency
of bleeding intolerance in these elderly patients.
Follow-up and Data Collection
All patients were carefully followed by both cardiac surgeons and cardi-
ologists. Clinical follow-up and echocardiographic results were obtained
before discharge from the hospital and at 1, 6, and 12months.We have com-
pleted 12 months of follow-up in our first 26 patients. We present data from
the 17 patients who survived more than 12 months for comparisons of pre-
operative baseline and 1-, 6-, and 12-month follow-up clinical and echocar-
diographic results.
Echocardiograms were reviewed by our senior echocardiographers. In-
traoperative and immediate postoperative acute myocardial infarction was
defined by electrocardiographic criteria, whereas acute myocardial infarc-
tion during follow-up was defined as an increase of troponin T levels asso-
ciated with clinical symptoms, electrocardiographic evidence of infarction,
or both. Procedure-related major bleeding is defined as significant blood168 The Journal of Thoracic and Cardiovascular Suloss caused by a difficult apical hemostasis and a requirement for blood
transfusion intraoperatively. Postoperative bleeding was defined as any sig-
nificant blood loss requiring surgical intervention, significant blood transfu-
sion (>2 units), or both.
Statistical Analysis
Data are presented as the mean  standard deviation. All echocardio-
graphic parameters and New York Heart Association (NYHA) class were
matched data from 17 patients who survived for longer than 12 months.
The 2-way analysis of variance model was used to compare echocardio-
graphic parameters (aortic valve area, mean transaortic pressure gradient,
aortic insufficiency, left ventricular ejection fraction, and mitral regurgita-
tion) and NYHA class between different time points. The paired t test
was used to compare the left ventricular mass index at the baseline level
and at 6 to 12 months after the procedure. The Kaplan–Meier method was
used to generate survival curves. The statistical analyses were performed
with the SAS (version 9.1.3) statistical software package.
RESULTS
Patients
The baseline characteristics of the 26 patients are shown
in Table 1. Significant comorbidities include severe periph-
eral vascular disease (77%), coronary artery disease (69%),
prior cardiac surgery (50%), moderate or severe mitral
regurgitation (43%), porcelain ascending aorta (42%), and
severe lung disease (27%). EuroSCORE, Logistic Euro-
SCORE, and Society of Thoracic Surgeons (STS) estimates
of operative mortality were 12%  4%, 37%  20%, and
11%  6%, respectively. Several patients were not
accepted for conventional AVR despite low estimates of
operative mortality because of porcelain ascending aorta,
severe lung disease, poor general condition, or end-stage
liver cirrhosis.
Intraoperative Outcome
Transapical transcatheter AVI through a left minithora-
cotomy without CPB was successfully performed in all 26
patients. Twenty patients received 26-mm and 6 patients
FIGURE 1. Three major components of the transapical aortic valve im-
plantation: balloon valvuloplasty, deployment, and assessment of the pros-
thetic valve. TEE, Transesophageal echocardiography.rgery c January 2009
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Treceived 23-mm prostheses. In 1 patient a second transcath-
eter bioprosthesis was implanted after the first transcatheter
bioprosthesis was deployed too low within the left ventricu-
lar outflow tract. Four patients with moderate paravalvular
regurgitation immediately after the deployment of biopros-
theses underwent redilation, with further expansion of the
prosthesis and satisfactory reduction in paravalvular regurgi-
tation in 3 patients. One patient died immediately after com-
pletion of the procedure in the operating room, probably as
a result of obstruction of the left coronary ostium by a native
bulky calcified aortic valve. This patient also had significant
intraoperative bleeding caused by difficult hemostasis at the
puncture site of the LV apex. There was no conversion to
open-heart AVR. Procedural characteristics are shown in
Table 2.
Early Clinical Outcome
Of the 26 patients, 20 were discharged from the hospital,
and 6 died in the hospital or within 30 days after valve im-
plantation. The 30-day mortality was 23%. The characteris-
tics of the 6 patients and the causes of death are listed in
TABLE 1. Baseline characteristics of 26 patients
Characteristics No. of patients %
Age (80.1  9.1 y)*
90 y 3 12
80–89 y 13 50
Female sex 13 50
Body mass index (kg/m2; 22.8  3.1)*
25 kg/m2 7 27
Body surface area (m2; 1.68  0.22)* 1.8 m2 9 35
New York Heart Association class
II 5 19
III 17 65
IV 3 12
Hypertension 20 77
Diabetes 2 8
Coronary artery disease 18 69
Severe lung disease 7 27
Cerebral ischemic event 7 27
Peripheral vascular disease 20 77
Prior cardiac surgery 13 50
Estimated glomerular filtration rate<60 mL/min 12 46
Ejection fraction<50% 5 19
Mitral regurgitation
III (moderate) 8 31
IV (severe) 3 12
Pulmonary hypertension (systolic pressure
>60 mm Hg)
6 23
Porcelain aorta 11 42
Smoking 16 62
Severe carotid disease 5 19
Atrial fibrillation 11 43
Permanent pacemaker 4 15
Hemoglobin<120 mg/L 10 38
*Mean  standard deviation.The Journal of Thoracic and CTable 3. Five of the 6 patients had logistic EuroSCOREs
of 20 or greater (20% to 58%), and 1 patient had a low
logistic EuroSCORE (2%) despite end-stage liver disease.
Twenty patients survived 30 days and had an average hospi-
tal stay of 9  5 days. The delayed hospital discharge was
mainly due to preoperative comorbidities and general debil-
itation. Early postoperative complications included major
gastrointestinal bleeding from peptic ulcer disease, heart
block, pneumonia/sepsis, thromboembolic event (ischemic
bowel), and stroke (Table 4).
Late Clinical Outcomes
All procedures (26 patients) were performed 12 or more
months before the last follow-up contact. Twenty patients
survived for more than 30 days, and 3 additional deaths
occurred between 30 days and 1 year (postoperative days
51, 85, and 89). These deaths were due to noncardiac causes,
including cancer and pneumonia. Seventeen patients re-
mained alive at the 12-month follow-up. Among 20 patients
who survived for more than 30 days, 12-month survival was
85%. Figure 2 shows the Kaplan–Meier survival after trans-
apical transcatheter AVI.
Late complications were uncommon in 20 survivors. One
patient had gastrointestinal bleeding, requiring blood trans-
fusion, and another patient needed chest tube drainage for
pleural effusion. There were no other significant valve-
related complications, such as stroke or transient ischemic
attack, myocardial infarction, major arrhythmia, endocardi-
tis, thromboembolic events, or valve structural deteriora-
tion/dysfunction during 12 months of follow-up.
In the 17 survivors the majority of the patients (near
80%) had NYHA class III and IV heart failure symptoms
before the procedure. Significant early improvement in
functional class was achieved in most patients, and more
than 80% had NYHA class I or II heart failure symptoms
at the 1-month follow-up. Some continued improvement in
functional class was observed during 6 to 12 months of
follow-up (Figure 3, F).
Echocardiographic Follow-up
All echocardiographic data used for comparisons were
obtained only from 17 matched survivors. Predischarge
TABLE 2. Procedural characteristics
Characteristics N ¼ 26 patients %
Aortic annulus diameter (mm)* 22  2
Aortic bioprosthesis
23 mm 6 23
26 mm 20 77
Successful valvuloplasty 26 100
Successful valve implantation 26 100
Postdeployment redilatation 4 15
Fluoroscopic time (min)* 12  3
*Mean  standard deviation.ardiovascular Surgery c Volume 137, Number 1 169
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Characteristics Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6*
Age (y)/sex 91/M 58/M 71/F 91//M 82/F 81/M
Severe lung disease Yes No Yes No No Yes
CAD Yes No No Yes No Yes
Stroke/TIA Yes No Yes No No Yes
Severe PVD Yes No Yes Yes Yes No
GFR<60 No No Yes Yes No Yes
Pulmonary HTN Yes No No Yes Yes No
LVEF (%) 40 70 60 60 35 65
NYHA class 4 3 4 2 3 3
Other significant morbidity Recent CHF,
feeding tube
End-stage liver
disease
Severe COPD Severe PVD ESRD, long-term
steroid
Severe COPD
EuroSCORE 16 2 14 11 14 10
Logistic EuroSCORE 58 2 51 20 44 20
STS estimates 14 1.6 9 10 24 11
Days to death 12 5 10 9 0 6
Causes of death Aspiration
pneumonia
Bleeding from chest tube
insertion and coagulopathy
Ischemic colitis
(embolism?)
Septic shock Possible left coronary
ostial obstruction
Stroke
CAD, Coronary artery disease; TIA, transient ischemic attack; PVD, peripheral vascular disease; GFR, glomerular filtration rate;HTN, hypertension; LVEF, left ventricular ejection
fraction; NYHA, New York Heart Association; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; STS, Society of
Thoracic Surgeons. *Underwent combined transapical aortic valve implantation and minimally invasive coronary artery bypass.transthoracic echocardiographic analysis documented a sig-
nificant increase in estimated aortic valve area from 0.5 
0.1 cm2 preoperatively to 1.7  0.5 cm2 (P< .0001) and
a significant reduction in transaortic mean gradient from
44.5 13.7 to 8.9 5.0 mm Hg (P<.0001). The prosthetic
valve area and transvalvular pressure gradient remained sta-
ble during 1 to 12 months of follow-up (Figure 3, A and B).
Echocardiography also documented excellent midterm pros-
thetic valve durability without structural or hemodynamic
deterioration during 12 months of follow-up.
The left ventricular ejection fraction increased after AVI
from a mean of 56%  13% preoperatively to 63% 
9% at 12 months (Figure 3, E), although this was not statis-
tically significant. The increase in ejection fraction was
mainly as a result of an improvement in the patients with pre-
operative left ventricular dysfunction. Three patients with
severe left ventricular dysfunction had more impressive im-
provement in ejection fraction from 33%  3% preopera-
tively to 57%  10% at 12 months of follow-up.
Moderate-to-severe mitral regurgitation was present at
baseline in 59% of the 17 survivors. A reduction in mitral
regurgitation was observed immediately after the procedure,
and 23% of the 17 survivors had moderate or severe MR at
12 months (Figure 3, D).
Valvular or paravalvular aortic insufficiency was deter-
mined bymeansof echocardiography.No survivors had aortic
insufficiency greater than mild (mild in 47% and trivial/none
in 53% of survivors) at 1 month after the procedure. The
degree of aortic insufficiency remained unchanged from 1 to
12months (Figure 3,C). Clinical hemolysiswas not observed.
In 9 survivors left ventricular mass indices were available
at baseline and at 6 to 12 months of follow-up. In these170 The Journal of Thoracic and Cardiovascular Supatients the left ventricular mass index decreased from
133  56 g/m2 preoperatively to 104  32 g/m2 at 6 to
12 months after the procedure, but there was no statistical
difference (P ¼ .123).
DISCUSSION
Open-heart AVR remains the gold standard for the treat-
ment of symptomatic severe aortic stenosis and is associated
with minimal operative mortality and morbidity in the ma-
jority of patients. However, surgical mortality rates increase
in the presence of comorbidities or the need for additional
TABLE 4. Early outcome after transapical aortic valve implantation
in 26 patients
Outcome
No. of patients
(total ¼ 26) %
Stroke or transient ischemic attack 1 4
Myocardial infarction 1 4
Procedure-related major bleeding 1 4
Postoperative bleeding 2 8
Atrioventricular block 3 12
Wound infection 0 0
Pneumonia/sepsis 2 8
Postoperative ventilation>10 h 2 8
Acute renal failure 0 0
Blood transfusion>2 units 3 12
Thromboembolic events 1 4
Ventilator time (h)* 6  4
Hospital stay for 20 patients
surviving>30 d (d)*
9  5
30-d mortality 6 23
12-mo survival 17 65%
*Mean  standard deviation.rgery c January 2009
Ye et al Evolving TechnologyFIGURE 2. Twelve-month follow-up of echocardiographic parameters and New York Heart Association (NYHA) functional class in 17 patients surviving
more than 12 months (matched data). *P< .0001 versus preoperative baseline. MR, Mitral regurgitation; Pre-op, preoperative; Post-op, postoperative; AR,
aortic regurgitation.E
Tcardiac procedures.21-28 A considerable number of potential
surgical candidates have significant comorbid conditions,
and cardiac surgery with CPB might pose risks that are un-
acceptable to them or their physicians.29,30 According to the
STS database (1998–2001), surgical AVR carries a rate of
serious complication or mortality of 16.8%. Although the
mortality of selected octogenarians undergoing cardiac sur-
gery compared with that of younger patients is only moder-
ately increased, their morbidity is clearly higher. Reported
mortality for septuagenarians and octogenarians undergoing
primary isolated AVR ranges from 6.6% to 16.7%, whereas
reported operative morbidity, including atrial fibrillation, in
elderly patients (>70 years old) after AVR with or without
coronary artery bypass was up to 64% to 76%.22,31,32
Transcatheter AVI is an evolving surgical procedure
developed in part to deal with an increasing preoperative
risk profile of the patient population with symptomatic aortic
valve disease. The clinical feasibility of the transapical trans-
catheter AVI has been well documented.11,12,19,20,33 This
report represents the longest follow-up data on transapical
transcatheter AVI in a relatively large number of patientsThe Journal of Thoracic and(n ¼ 26) being followed clinically and echocardiographi-
cally for at least 12 months. These patients were judged to
be poor candidates for routine cardiac surgery by 2 indepen-
dent surgeons because of an unacceptably high risk of oper-
ative mortality and particularly morbidity. These patients
were also declined for transcatheter transfemoral AVI,
mainly because of severe aortic or peripheral vascular
FIGURE 3. Kaplan–Meier survival. Pts, Patients.Cardiovascular Surgery c Volume 137, Number 1 171
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Tdisease, or had failed transfemoral AVI. The estimated oper-
ative mortality was 37% 20% by using the logistic Euro-
SCORE and 11%  6% by using the STS Risk Calculator.
Our observed 30-day mortality in this initial cohort of pa-
tients was 23%, which is higher than STS estimates. How-
ever, the prediction models are based on retrospective
analysis of patients who underwent conventional AVR,
which contains a few patients with risk profiles similar to
those of our patient cohort. Many risk factors that were
observed in our patients are not well reflected by these scor-
ing systems, such as end-stage liver disease, prolonged pre-
operative hospital stay, general deconditioning, immobility
because of other medical conditions, significant abnormali-
ties of other valves, severity of peripheral vascular and aortic
disease, and end-stage lung disease. These risk factors are
also the major contribution to the early and late mortality
and morbidity after transapical transcatheter AVI, which
would explain our relatively high 30-day operative mortal-
ity. Nine of our 26 patients had EuroSCOREs of greater
than 50%, several patients had end-stage lung and liver dis-
eases, and the majority of our patients had severe systemic
vasculopathy. We believe that patient selection has a direct
effect on operative mortality. Furthermore, the learning
curve of the novel procedure would also have an effect on
our operative mortality because the operative mortality in
our last 30 patients decreased to 13% (unpublished data).
Early major complications are observed in 9 patients, of
whom 6 died within 30 days. Early operative mortality could
be reduced significantly by preventing perioperative compli-
cations, such as bleeding and pneumonia, and appropriate
patient selection. The causes of late mortality (11.5%) are
noncardiac, including pneumonia in 2 patients and cancer
in 1 patient. There were no late valve-related or procedure-
related complications in this cohort of patients during the
12 months of follow-up.
The transapical approach for transcatheter AVI is reliable,
with acceptable operative risks and favorable clinical and
echocardiographic outcomes in the majority of these very
high-risk patients. Postoperative recovery, length of hospital
stay, and late survival are largely dependent on preoperative
comorbidities and general health conditions. The procedure
provides immediate relief of symptoms related to aortic ste-
nosis, such as angina, presyncope, or syncope, and continued
improvement in heart failure symptoms during the 12months
of follow-up. The majority of survivors (94%) had NYHA
class I or II heart failure symptoms at 12months after the pro-
cedure. Most of the survivors were very satisfied with their
cardiac conditions and living independently at follow-up.
Transcatheter bioprosthetic valve function appeared ex-
cellent, without evidence of structural valve deterioration/
dysfunction or inadequate fixation at 12months after implan-
tation. Trivial-to-mild paravalvular regurgitation was com-
mon immediately after deployment of the prostheses but
remained stable at 12 months. More significant paravalvular172 The Journal of Thoracic and Cardiovascular Surregurgitation resulting from incomplete deployment of the
bioprosthesis can be effectively reduced by repeat balloon
dilation.34 This has been demonstrated in 2 patients. How-
ever, repeat balloon dilation is not effective in reducing
significant paravalvular regurgitation caused by suboptimal
positioning of the bioprosthesis, which was seen in 1 patient.
Concomitant severe mitral regurgitation or significant
coronary artery disease in the presence of severe aortic ste-
nosis is generally considered an indication for a combined
surgical procedure with an attendant increase in operative
mortality and morbidity, particularly in patients with ad-
vanced age and significant comorbid conditions. In the pres-
ent series 59% of patients had moderate-to-severe mitral
regurgitation. A decrease in mitral valve regurgitation and
an increase in left ventricular function after transapical
AVI suggest that a conservative approach to coexisting mi-
tral valve regurgitation might be a reasonable approach in se-
lected patients.
Coronary artery disease was present in 69% of patients.
Although prior coronary artery grafting and angioplasty
had been performed in the distant past in 31% and 19%, re-
spectively, many patients had residual nonrevascularized
coronary disease. One patient underwent prophylactic pre-
procedural angioplasty, and 1 patient had a combined mini-
mally invasive coronary artery bypass and transapical AVI.
No early and late myocardial infarction in this cohort of pa-
tients was observed during 12 months of follow-up, which
suggests that aggressive interventions for moderate coronary
artery disease before the transapical procedure might not
routinely be necessary.
The risk of perioperative stroke appeared low because it
was observed only in 1 (3.8%) patient during 12 months of
follow-up. The low incidence of stroke, particularly with
the transapical approach, is likely a result of (1) avoidance
of passing a large catheter through the aortic arch and ascend-
ing aorta, as occurs during transfemoral retrograde AVI; (2)
an antegrade, rather than retrograde, approach to the calcified
aortic valve; or both. Obstruction of the coronary ostium by
a bulky calcified native valve, the transcatheter bioprosthesis,
or both has been documented, but the incidence appears in-
frequent.10 We observed this complication in 1 patient in
this series. Preoperative assessment of the amount of the cal-
cification, location of the bulky calcification, location of the
coronary ostia, and anatomy of the aortic root might reduce
the risk of this fatal complication.
Device embolization is a documented complication35 but
was not observed during early and late follow-up in this
cohort undergoing transapical AVI. Theoretically, better
coaxial positioning and stabilization of the device during
deployment can be achieved with the transapical approach
because of a short straight line from the apex to the annulus,
relative to the transfemoral approach. Given the small num-
bers treated to date, this remains to be evaluated. We believe
that the experience of surgeons, interventional cardiologists,gery c January 2009
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Tand echocardiographers plays a major role in avoiding this
complication.
In summary, our 12-month clinical and echocardio-
graphic outcomes suggest that transapical transcatheter
AVI is a viable alternative to conventional open-heart
AVR in selected high-risk patients with symptomatic severe
aortic stenosis. Although excellent structural and hemody-
namic stability of the bioprosthesis is demonstrated at 12
months of follow-up, in vivo long-term durability of the
transcatheter bioprosthesis remains to be determined. Both
the technology and techniques in transapical transcatheter
AVI continue to evolve, and we are all in a process of learn-
ing who will be the most appropriate candidates. Conven-
tional open-heart AVR remains the first-line therapy for
symptomatic severe aortic stenosis.
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